Pharmacology of Sevoflurane

Introduction/Overview

Sevoflurane represents a cornerstone agent in modern inhalational anesthesia, belonging to the class of halogenated ethers. Its introduction marked a significant advancement in anesthetic practice due to its favorable pharmacokinetic and pharmacodynamic profile, particularly its low blood-gas solubility coefficient which facilitates rapid induction and emergence from anesthesia. The clinical relevance of sevoflurane is profound, as it is extensively employed for the induction and maintenance of general anesthesia across a wide spectrum of surgical procedures and patient populations, from pediatric to geriatric. Its non-pungent odor and minimal airway irritation further distinguish it from other volatile agents, making it especially valuable for inhalational induction in children and adults with reactive airways.

The importance of understanding the pharmacology of sevoflurane extends beyond its routine administration. A comprehensive grasp of its mechanism of action, biotransformation pathways, and potential toxicities is essential for the safe and effective practice of anesthesia. This knowledge enables clinicians to anticipate drug interactions, manage adverse effects, and tailor anesthetic plans for patients with specific comorbidities, such as renal or hepatic impairment. Furthermore, the ongoing research into the potential neurotoxic effects of volatile anesthetics, particularly in vulnerable developing brains, underscores the necessity for a nuanced and evidence-based application of this agent.

Learning Objectives

• Describe the chemical classification of sevoflurane and its position among other inhaled anesthetics.
• Explain the proposed molecular and cellular mechanisms of action underlying sevoflurane-induced anesthesia and immobility.
• Analyze the pharmacokinetic profile of sevoflurane, including factors influencing its uptake, distribution, metabolism, and elimination.
• Identify the primary clinical indications, common adverse effects, and serious toxicities associated with sevoflurane administration.
• Evaluate special considerations for the use of sevoflurane in specific patient populations, including pediatric, geriatric, and those with organ dysfunction.

Classification

Sevoflurane is systematically classified within the broader category of general anesthetics, specifically as a volatile or inhalational anesthetic agent. Its chemical classification places it among the halogenated methyl isopropyl ethers. The molecular structure is characterized by a fluorinated ether backbone, specifically fluoromethyl 2,2,2-trifluoro-1-(trifluoromethyl)ethyl ether. This structure is distinct from other commonly used volatile agents.

Chemical and Pharmacologic Classification

From a chemical perspective, sevoflurane is a fully fluorinated compound. Unlike its predecessor isoflurane, which is a chlorinated compound, sevoflurane contains no chlorine atoms. This fluorination contributes to its stability and specific physicochemical properties, most notably its low blood-gas partition coefficient of approximately 0.65. This property is a primary determinant of its rapid pharmacokinetics. Compared to other agents in its class, sevoflurane possesses the most favorable blood-gas solubility among contemporary volatile anesthetics, with desflurane being a close competitor. Its classification as an ether, rather than an alkane like halothane, is also significant, as ethers are generally less associated with cardiac sensitization to catecholamines and have a different metabolic profile.

Mechanism of Action

The precise mechanism by which sevoflurane, and indeed all general anesthetics, produce their characteristic effects—amnesia, analgesia, immobility, and unconsciousness—remains an area of active investigation. The prevailing theory is the unitary theory of anesthesia, which posits that these agents act by modulating synaptic transmission in the central nervous system, rather than through a single specific receptor. The primary site of action is widely accepted to be ligand-gated ion channels, with enhancement of inhibitory neurotransmission and suppression of excitatory neurotransmission being central to their effects.

Molecular and Cellular Targets

At the molecular level, sevoflurane exhibits a promiscuous interaction with multiple neuronal ion channels. Its most potent effects are mediated through potentiation of the γ-aminobutyric acid type A (GABA_A) receptor. Sevoflurane binds to specific sites on this pentameric chloride channel, distinct from the binding sites for benzodiazepines or barbiturates, and prolongs the duration of chloride channel opening. This increased chloride influx hyperpolarizes the neuronal membrane, rendering the neuron less likely to fire an action potential, thereby producing central nervous system depression.

Concurrently, sevoflurane inhibits excitatory neurotransmission. It acts as a non-competitive antagonist at the N-methyl-D-aspartate (NMDA) subtype of glutamate receptors, reducing calcium influx. Furthermore, it potentiates other inhibitory channels, such as glycine receptors in the spinal cord and brainstem, and two-pore domain potassium (K_2P) channels like TREK-1. Activation of these background potassium channels leads to potassium efflux and membrane hyperpolarization. The immobilizing effect of inhaled anesthetics, a key component of surgical anesthesia, is primarily mediated through action on the spinal cord, involving suppression of motor neuron excitability via these combined mechanisms on GABA_A, glycine, and NMDA receptors.

Macroscopic Effects and the Minimum Alveolar Concentration

The net effect of these molecular interactions is a dose-dependent depression of central nervous system function. At the macroscopic level, sevoflurane produces a reversible, global disruption of neural networks, particularly those involved in consciousness and memory formation, such as the thalamocortical and hippocampal circuits. The potency of inhaled anesthetics is standardized using the concept of Minimum Alveolar Concentration (MAC). MAC is defined as the alveolar concentration of an inhaled anesthetic, at one atmosphere, that prevents movement in 50% of subjects in response to a standardized surgical stimulus. The MAC of sevoflurane in a healthy, young adult is approximately 2.0%. This value serves as the primary dosing metric, with typical maintenance doses ranging from 1.0 to 2.5 MAC, depending on the use of adjuvant agents like opioids or sedatives.

Pharmacokinetics

The pharmacokinetics of inhaled anesthetics are uniquely described by their uptake from the lungs into the blood and subsequent distribution to tissues, particularly the vessel-rich group (brain, heart, liver, kidneys), which determines the speed of induction and recovery. The principles governing these processes are largely shared among volatile agents, but the specific physicochemical properties of sevoflurane confer a distinct clinical profile.

Absorption and Uptake

Administration is exclusively via inhalation through a calibrated vaporizer. Absorption occurs across the alveolar-capillary membrane. The rate of rise of the alveolar concentration (F_A) toward the inspired concentration (F_I) is governed by several factors. The most critical is the blood-gas partition coefficient (λ_b/g), which is a measure of the solubility of the anesthetic in blood. Sevoflurane has a low λ_b/g of 0.65, meaning it has low solubility in blood. A low solubility agent does not readily leave the alveolar gas to dissolve in the pulmonary blood, allowing the alveolar partial pressure to rise rapidly. This results in a rapid increase in the arterial partial pressure and, consequently, a swift delivery of the anesthetic to the brain. This property is the primary reason for sevoflurane’s rapid induction and emergence characteristics. Other factors influencing uptake include alveolar ventilation, cardiac output, and the alveolar-to-venous partial pressure gradient.

Distribution

Once absorbed, sevoflurane is distributed via the systemic circulation. Its distribution is influenced by tissue blood flow and the tissue-blood partition coefficient. The brain, being part of the vessel-rich group (VRG) that receives approximately 75% of the cardiac output, achieves equilibrium with arterial blood rapidly, typically within 10-15 minutes. The muscle group (MG) and fat group (FG) have much lower perfusion rates and higher affinity for lipid-soluble anesthetics, leading to slower uptake. However, due to sevoflurane’s low solubility in all tissues, the rate of equilibration and the total amount taken up by these peripheral compartments are less than with more soluble agents like isoflurane or halothane. This minimizes the “tissue reservoir” effect, contributing to faster recovery.

Metabolism

Sevoflurane undergoes biotransformation primarily in the liver via the cytochrome P450 system, specifically the CYP2E1 isoform. The extent of metabolism is approximately 3-5%, which is greater than that of isoflurane (0.2%) or desflurane (0.02%) but significantly less than that of halothane (20%). The primary metabolic pathway involves oxidative defluorination, resulting in the production of inorganic fluoride ions (F^–) and hexafluoroisopropanol (HFIP). HFIP is rapidly conjugated with glucuronic acid and excreted renally. The production of fluoride ions is a point of pharmacokinetic and toxicological interest due to the potential for nephrotoxicity, although the clinical risk with sevoflurane is considered low under standard conditions.

Excretion and Elimination

The overwhelming majority of sevoflurane (95-97%) is eliminated unchanged via exhalation through the lungs. This process is the reverse of uptake. Because of its low solubility, the alveolar partial pressure falls rapidly once administration is discontinued, leading to a swift decline in brain partial pressure and prompt emergence from anesthesia. A small fraction is eliminated as metabolites in the urine. The context-sensitive half-time, a more clinically relevant measure of recovery than elimination half-life for inhaled anesthetics, is very short for sevoflurane, even after prolonged administration, due to its low tissue solubility.

Therapeutic Uses/Clinical Applications

Sevoflurane is approved for the induction and maintenance of general anesthesia in inpatient and outpatient surgical procedures for adult and pediatric patients. Its applications are broad due to its versatile pharmacologic profile.

Primary Indications

• Inhalational Induction: Sevoflurane is the agent of choice for inhalational induction, particularly in pediatric patients and adults who are needle-phobic or have difficult intravenous access. Its non-pungent odor and minimal airway irritation allow for a smooth, rapid induction without causing coughing, breath-holding, or laryngospasm, which are more common with other agents like isoflurane or desflurane.
• Maintenance of Anesthesia: It is extensively used for the maintenance phase of general anesthesia. It can be used as a sole agent or, more commonly, as part of a balanced anesthetic technique combined with intravenous opioids, neuromuscular blocking agents, and other adjuvants. Its rapid adjustability and low solubility allow for precise control of anesthetic depth.
• Outpatient/Ambulatory Surgery: The rapid emergence and recovery profile of sevoflurane make it ideally suited for outpatient surgical settings, facilitating faster discharge times and potentially reducing post-anesthesia care unit (PACU) stays.

Other Clinical Applications

Beyond its primary indications, sevoflurane finds use in several specific clinical scenarios. It is often employed in patients with reactive airway disease, such as asthma or chronic obstructive pulmonary disease (COPD), due to its bronchodilatory properties. Its hemodynamic profile may be considered advantageous in certain cardiac patients, though this requires careful titration. Sevoflurane has also been investigated for its potential organ-protective effects, including preconditioning of the myocardium against ischemic injury, although this remains a topic of research and is not a standard indication for its use.

Adverse Effects

While generally safe when administered by trained personnel with appropriate monitoring, sevoflurane is associated with a range of dose-dependent and idiosyncratic adverse effects affecting multiple organ systems.

Common Side Effects

• Cardiovascular: Sevoflurane causes a dose-dependent decrease in systemic vascular resistance and myocardial contractility, leading to reductions in arterial blood pressure. Heart rate typically remains stable or may decrease slightly. These effects are generally predictable and manageable with fluid administration or vasopressors.
• Respiratory: It produces dose-dependent respiratory depression, decreasing tidal volume and increasing respiratory rate, though not sufficiently to maintain minute ventilation. It also depresses the ventilatory response to hypercapnia and hypoxia. Sevoflurane is a bronchodilator, which can be beneficial.
• Central Nervous System: At high concentrations, sevoflurane can increase cerebral blood flow and intracranial pressure, a consideration in neurosurgical patients. Emergence phenomena, including agitation, delirium, and postoperative nausea and vomiting (PONV), are common, particularly in children and the elderly.
• Hepatic: Transient, asymptomatic elevations in liver transaminases have been reported.

Serious and Rare Adverse Reactions

• Malignant Hyperthermia (MH): Sevoflurane, like all volatile anesthetic agents, is a potent triggering agent for malignant hyperthermia in susceptible individuals. MH is a life-threatening pharmacogenetic disorder of skeletal muscle calcium regulation characterized by hypermetabolism, muscle rigidity, hyperthermia, acidosis, and hyperkalemia. Immediate discontinuation of the trigger agent and administration of dantrolene sodium are required.
• Compound A Nephrotoxicity: When sevoflurane is exposed to carbon dioxide absorbents containing strong bases (particularly barium hydroxide lime or soda lime at low fresh gas flows < 2 L/min), it can degrade to fluoromethyl-2,2-difluoro-1-(trifluoromethyl)vinyl ether (Compound A). Compound A is a dose-dependent nephrotoxin in rats. In humans, studies have shown transient increases in biochemical markers of renal injury (e.g., albumin, glucose, α-glutathione S-transferase) with prolonged low-flow anesthesia, but no conclusive evidence of clinically significant renal failure in patients with normal renal function. The use of fresh gas flows above 2 L/min when using older absorbents is recommended to minimize this risk.
• Fluoride Ion Nephrotoxicity: Metabolism releases inorganic fluoride. Plasma fluoride levels peak 2 hours post-operatively and typically remain below the theoretical nephrotoxic threshold of 50 µM. However, in patients with pre-existing renal impairment or after very prolonged administration, levels may exceed this, warranting caution.
• Postoperative Cognitive Dysfunction (POCD): There is ongoing investigation into the potential for volatile anesthetics, including sevoflurane, to contribute to postoperative cognitive decline, particularly in the very young and the elderly. The evidence is complex and not yet definitive.

Black Box Warnings

Sevoflurane does not currently carry a black box warning from the U.S. Food and Drug Administration. However, its labeling includes strong warnings regarding its role as a trigger for malignant hyperthermia and the potential for renal injury associated with Compound A production, especially during low-flow anesthesia.

Drug Interactions

The pharmacodynamic effects of sevoflurane are significantly influenced by concomitant drug administration, necessitating careful dose adjustment and vigilant monitoring.

Major Pharmacodynamic Interactions

• Non-Depolarizing Neuromuscular Blocking Agents (NMBAs): Sevoflurane potentiates the effects of both aminosteroid (e.g., rocuronium, vecuronium) and benzylisoquinolinium (e.g., atracurium, cisatracurium) NMBAs. This synergism reduces the required dose of the NMBA by approximately 20-50% and prolongs its duration of action. Monitoring of neuromuscular function with a peripheral nerve stimulator is essential.
• Opioids and Sedative-Hypnotics: Concomitant use of opioids (e.g., fentanyl, remifentanil) or intravenous hypnotics (e.g., propofol, benzodiazepines) produces additive or synergistic depression of the central nervous, cardiovascular, and respiratory systems. This interaction is the basis of balanced anesthesia but requires reduced doses of all agents to avoid profound hypotension, bradycardia, or apnea.
• Other Cardiovascular Drugs: The hypotensive effect of sevoflurane may be exaggerated by concomitant use of antihypertensive medications, diuretics, or other vasodilators. Beta-blockers may augment bradycardia. The sensitization of the myocardium to catecholamines, while less pronounced than with halothane, may still be clinically relevant, potentially increasing the risk of arrhythmias if exogenous catecholamines (e.g., in local anesthetic solutions) are administered.

Contraindications

Absolute contraindications to sevoflurane are few but critical. The primary contraindication is a known or suspected susceptibility to malignant hyperthermia, based on personal or family history. A history of severe, unexplained hepatic adverse reactions (e.g., hepatitis, jaundice) following prior exposure to halogenated anesthetics may also contraindicate its use, due to the rare possibility of immune-mediated halothane hepatitis-like cross-reactivity, though this is far less common with sevoflurane. It is contraindicated for use in patients with known hypersensitivity to sevoflurane or other halogenated agents.

Special Considerations

The safe use of sevoflurane requires adaptation of its administration based on specific patient characteristics and physiological states.

Pregnancy and Lactation

Sevoflurane is classified as Pregnancy Category B. Animal reproduction studies have not demonstrated a risk to the fetus, but no adequate, well-controlled studies exist in pregnant women. It crosses the placenta readily. Its use during pregnancy, particularly in the first trimester, should be reserved for situations where the benefit clearly justifies the potential risk to the fetus, typically during necessary surgical procedures. During labor and delivery, it can be used for analgesia (e.g., in a sub-anesthetic concentration via a dedicated vaporizer) or for cesarean section. It is excreted in human milk in very small amounts; however, due to its rapid elimination from the mother and the small quantities involved, breastfeeding can generally be resumed shortly after recovery from anesthesia.

Pediatric Considerations

Sevoflurane is widely used in pediatric anesthesia. The MAC value is age-dependent, being highest in infants (approximately 3.3% for a 1-6 month old) and decreasing with age to the adult value of 2.0%. Inhalational induction with sevoflurane is a standard technique. A well-recognized concern is the higher incidence of emergence agitation or delirium (EA/ED) in children, characterized by inconsolable crying, restlessness, and disorientation. The etiology is multifactorial but is associated with sevoflurane. Strategies to mitigate this include adequate postoperative analgesia, a calm recovery environment, and pre- or intraoperative administration of agents like dexmedetomidine, fentanyl, or midazolam.

Geriatric Considerations

In elderly patients, MAC decreases linearly with age, approximately 6% per decade after age 40. For an 80-year-old, the MAC may be as low as 1.0-1.2%. This increased sensitivity necessitates a significant reduction in the delivered concentration to avoid cardiovascular depression and delayed emergence. Elderly patients are also more susceptible to postoperative cognitive dysfunction and delirium. The rapid emergence profile of sevoflurane may be advantageous in this population to minimize residual sedative effects.

Renal and Hepatic Impairment

Renal Impairment: Caution is advised in patients with pre-existing renal insufficiency (creatinine clearance < 30 mL/min). While the risk of Compound A nephrotoxicity remains controversial, it may be prudent to avoid prolonged low-flow sevoflurane anesthesia in this population and to maintain fresh gas flows above 2 L/min. The significance of elevated fluoride ions is also greater if renal excretory capacity is compromised.

Hepatic Impairment: As sevoflurane is metabolized by the liver, severe hepatic impairment could theoretically alter its pharmacokinetics, though its low metabolic rate makes this less consequential than for other drugs. The primary concern is the potential for exacerbating pre-existing hepatic encephalopathy due to its CNS depressant effects. Volatile anesthetics also reduce hepatic blood flow, which could be detrimental in patients with compromised hepatic perfusion. No specific dose adjustment guidelines exist, but careful titration and monitoring are warranted.

Summary/Key Points

• Sevoflurane is a fluorinated methyl isopropyl ether inhalational anesthetic with a low blood-gas partition coefficient (0.65), enabling rapid induction and emergence.
• Its mechanism of action involves potentiation of inhibitory GABA_A and glycine receptors and inhibition of excitatory NMDA receptors, leading to a dose-dependent depression of CNS function, quantified by MAC (≈2.0% in adults).
• Pharmacokinetically, it is primarily eliminated unchanged via the lungs (95-97%), with 3-5% metabolized by hepatic CYP2E1 to inorganic fluoride and hexafluoroisopropanol.
• It is the agent of choice for inhalational induction, especially in pediatrics, and is widely used for maintenance of anesthesia in inpatient and outpatient settings.
• Common adverse effects include dose-dependent hypotension, respiratory depression, and emergence agitation. Serious risks include triggering malignant hyperthermia and potential, though debated, nephrotoxicity from the degradation product Compound A during low-flow anesthesia.
• It potentiates neuromuscular blocking agents and synergizes with opioids, requiring dose reductions. It is contraindicated in patients with known susceptibility to malignant hyperthermia.
• Special considerations include higher MAC in infants, lower MAC in the elderly, and cautious use in patients with severe renal or hepatic impairment, with attention to fresh gas flow rates.

Clinical Pearls

• For a smooth inhalational induction in a child, start with 8% sevoflurane in 50-70% nitrous oxide and oxygen, then titrate down after loss of consciousness.
• To minimize the risk of Compound A formation, maintain fresh gas flows above 2 L/min when using conventional carbon dioxide absorbents, especially for procedures expected to last longer than 2 hours.
• In the elderly, reduce the initial inspired concentration significantly; a MAC of 1.0% may be sufficient for maintenance when combined with other agents.
• Always have a supply of dantrolene readily available whenever a volatile anesthetic like sevoflurane is in use, due to the risk of malignant hyperthermia.
• Emergence agitation in children can often be mitigated by ensuring adequate analgesia and considering a small dose of fentanyl (0.5-1 µg/kg) or propofol (0.5-1 mg/kg) at the end of surgery.

References

1. Rang HP, Ritter JM, Flower RJ, Henderson G. Rang & Dale's Pharmacology. 9th ed. Edinburgh: Elsevier; 2020.
2. Whalen K, Finkel R, Panavelil TA. Lippincott Illustrated Reviews: Pharmacology. 7th ed. Philadelphia: Wolters Kluwer; 2019.
3. Trevor AJ, Katzung BG, Kruidering-Hall M. Katzung & Trevor's Pharmacology: Examination & Board Review. 13th ed. New York: McGraw-Hill Education; 2022.
4. Katzung BG, Vanderah TW. Basic & Clinical Pharmacology. 15th ed. New York: McGraw-Hill Education; 2021.
5. Golan DE, Armstrong EJ, Armstrong AW. Principles of Pharmacology: The Pathophysiologic Basis of Drug Therapy. 4th ed. Philadelphia: Wolters Kluwer; 2017.
6. Brunton LL, Hilal-Dandan R, Knollmann BC. Goodman & Gilman's The Pharmacological Basis of Therapeutics. 14th ed. New York: McGraw-Hill Education; 2023.
7. Whalen K, Finkel R, Panavelil TA. Lippincott Illustrated Reviews: Pharmacology. 7th ed. Philadelphia: Wolters Kluwer; 2019.
8. Rang HP, Ritter JM, Flower RJ, Henderson G. Rang & Dale's Pharmacology. 9th ed. Edinburgh: Elsevier; 2020.